Tetrabenazine in the treatment of Huntington's disease

Neuropsychiatric Disease and Treatment

Volumn 3, Issue 5, 2007, Pages 545-551

  Paleacu, Diana ^a,b  

^a ABARBANEL MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Chorea; Huntington's disease; Tetrabenazine

Indexed keywords

CATECHOLAMINE; PLACEBO; RESERPINE; TETRABENAZINE;

AKATHISIA; BALANCE DISORDER; BLURRED VISION; CHOREA; CONFUSION; DEPRESSION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSPHAGIA; DYSTONIA; GAIT DISORDER; GASTROINTESTINAL SYMPTOM; GILLES DE LA TOURETTE SYNDROME; HALLUCINATION; HEADACHE; HUMAN; HUNTINGTON CHOREA; HYPERKINESIA; HYPOTENSION; INSOMNIA; INVOLUNTARY MOVEMENT; MEMORY DISORDER; MYOCLONUS; NAUSEA; NERVOUSNESS; NEUROLOGIC DISEASE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PANIC; PARANOIA; PARESTHESIA; PARKINSONISM; PNEUMONIA; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; SORE THROAT; SUICIDE; TARDIVE DYSKINESIA; TIC; TREMOR; VOMITING; WEAKNESS;

EID: 36048940046     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Ashcroft GW, Macdougall EJ, Barker PA. 1961. A comparison of tetrabenazine and chlorpromazine in chronic schizophrenia. J Ment Sci, 107:287-93.
2. Asher SW, Aminoff MJ. 1981. Tetrabenazine and movement disorders. Neurology, 31:1051-4.
3. Bartels M, Zeller E. 1984. Tetrabenazine (Nitoman) therapy of chronic spontaneous oral dyskinesia. A video- and EMG-controlled study. Eur Arch Psychiatry Neurol Sci, 234:172-4.
4. Boghen DR, Lesser RL. 2000. Blepharospasm and henufacial spasm. Curr Treat Options Neurol, 2:393-400.
5. andrup E. 1960. Reserpin og tetrabenacin ved chorea Huntington. Nordisk Medicin, 4:968-9.
6. Burke RE, Fahn S, Mayeux R, et al. 1981. Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease Neurology, 31:1022-5.
7. Duran E, Chacon JR. 200 1. Spasmodic torticollis and vertebral hemangioma. Rev Neurol, 32:60-2.
8. Erickson JD, Schafer MK, Bonner TI, et al. 1996. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci USA, 93:5166-71.
9. Falm S. 1985. A therapeutic approach to tardive dyskinesia. J Clin Psychiatry, 46:19-24.
10. Faulstich ME, Carnrike CL Jr, Williamson DA. 1985. Blepharospasm and Meige syndrome: a review of diagnostic, aetiological and treatment approaches. Psychosom Res, 29:89-94.
11. Fog R, Pakkenberg H. 1970. Combined nitoman-pimozide treatment of Huntington's chorea and other hyperkinetic syndromes. Acta Neurol Scand, 46:249-51.
12. Gilligan BS, Wodak J, Veale 1972. Tetrabenazine in the treatment of extrapyramidal dyskinesias. Med J Aust, 2:1054-6.
13. Gimenez-Roldan S, Mateo D. 1989. Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements Neurologia, 4:282-7.
14. Gonzalez AM, Walther D, Pazos A, et al. 1994. Synaptic vesicular monoamine transporter expression: distribution and pharmacologic profile. Mol Brain Res, 22:219-26.
15. Huang CY, McLeod JG, Holland et al. 1976. Tetrabenazine in the treatment of Huntington's chorea. Med J Aust, 1:583-4.
16. Hunter C, Wang A, Vuong K. 2002. Age-related tolerability of tetrabenazine. Mov Disord, 17(Suppl 5): S41.
17. Huntington Study Group. 2006. Tetrabenazine as an antichorea therapy in Huntington's disease: a random controlled trial Neurology, 66:366-72.
18. Jankovic J. 1982. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol, 11:41-7.
19. Jankovic J. 1983. Tetrabenazine in the treatment of hyperkinetic movement disorders. Adv Neurol, 37:277-89.
20. Jankovic J, Beach J. 1997. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology, 48:358-62.
21. Jankovic J, Beach J, Ashizawa T. 1995. Emotional and functional impact of DNA testing on patients with symptoms of Huntington's disease. J Med Genet, 32:516-18.
22. Jankovic J, Glaze DG, Frost JD Jr. 1984. Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome Neurology, 34:688-92.
23. Jankovic J, Orman J. 1988. Tetrabenazine therapy of dystonia, chores, tics, and other dyskinesias. Neurology, 38:3 91-4.
24. Jankovic J, Rohaidy H. 1987. Motor, behavioral and pharmacologic findings in Tourette's syndrome. Can J Neurol Sci, 14(3 Suppl):541-6.
25. Jimenez-Jimenez FJ, Garcia-Ruiz PJ. 2001. Pharmacological options for the treatment of Tourette's disorder. Drugs, 61:2207-20.
26. Kanjilal GC, Matheson B. 1962. A trial of tetrabenazine (Nituman) in disturbed mentally subnormal patients. J Ment Sci, 108:225-8.
27. Kenney C, Jankovic J. 2006. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother, 6:7-17.
28. Kidd DW, McLellan DL. 1972. Self-poisoning with tetrabenazine. Br J Clin Pract, 26:179-80.
29. Kingston D. 1979. Tetrabenazine for involuntary movement disorders. Med J Aus, 1:628-30.
30. Lane JD, Smith JE, Shea PA. 1976. Neurochemical changes following the administration of depleters of biogenic monoamines. Life Sci, 19:1663-7.
31. Lingjerde O. 1963. Tetrabenazine (Nitoman) in the treatment of psychoses. Acta Psychiatrica Scand, Suppl 170:158-209.
32. Manji H, Howard RS, Miller DH, et al. 1998. Status dystonicus: the syndrome and its management. Brain, 121:243-52.
33. Masuo Y, Pélaprat D, Scherman D, et al. 1990. [3H]Dihydrotetrabenazine, a new marker for the visualization of dopaminergic denervation in the rat striatum Neurosci Lett, 114:45-50.
34. Mateo D, Munoz-Blanco JL, Gimenez-Rodan S. 1992. Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease. Clin Neuropharmacol, 15:63-8.
35. Mc Lellan DL, Chalmers RJ, Johnson RH. 1974. A double blind trial of tetrabenazine, thiopropazate and placebo in patients with chorea, The Lancet, 26:104-7.
36. Mikkelsen BO. 1983. Tolerance of tetrabenazine during long-term treatment. Acta Neurol Scand, 68:57-60.
37. Moss JH, Stewart DE. 1986. latrogenic paTkinsonism in Huntington's chorea. Can J Psychiatry, 31:865-6.
38. Ondo WG, Hanna PA, Jankovic J. 1999. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am. J Psychiatry, 156:1279-91.
39. Ondo WG, Tintner R, Thomas M, et al. 2002. Tetrabenazine Treatment for Huntington's Disease-Associated Chorea. Clin Neuropharmacol, 25:300-2.
40. Ossemann M, Sindic CJ, Laterre C. 1996.Tetrabenazine as a cause of neuroleptic malignant syndrome. Mov Disord, 11:95.
41. Paleacu D, Giladi N, Moore O, et al. 2004. Tetrabenazine treatment in movement disorders. Clin Neuropharmacol, 27:230-3.
42. Pearson SJ, Reynolds G P. 1988. Depletion of monoamine transmitters by tetrabenazine in brain tissue in, Huntington's disease. Neuropharmacology, 27:717-19.
43. Pettibone DJ, Totaro JA, Pflueger A.B. 1984. Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants. Eur J Pharmacol, 20:425-30.
44. Pletscher A, Brossi A, Gey K. 1962. Benzoquinolizine derivatives: a new class of monoamine decreasing drugs with psychotropic action. International Review of Neurobiology, 4:275-306.
45. Quinn GP, Shore PA, Brodie BB. 1959. Biochemical and pharmacological studies of RO 1-9569 (tetrabenazine), a nonindole tranquilizing agent with reseipine-like effects. J Pharmacol Exp Ther, 127:103-9.
46. Raja M. 1998. Managing antipsychotic-induced acute and tardive dystonia. Drug Saf, 9:57-72.
47. Reches A, et al. 1983. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in Tat brain. J Pharmacol Exp Ther, 225:515-21.
48. Roberts MS, McLean S, Millingen KS, et al. 1986. The pharmacokinetics of tetrabenazine and its hydroxy metabolite in patients treated for involuntary movement disorders. Eur J Clin Pharmacol, 29:703-8.
49. Roberts MS, Watson HM, Mc Lean, et al. 1981. Detemiination of therapeutic plasma concentrations of tetrabenazine and an active metabolite by high-performance liquid chromatography. J Chromatagr, 226:175-82.
50. Sajatovic M, Verbanac P, Ramirez F, et al. 1991. Clozapine treatment of psychiatric syndromes resistant to neuroleptic treatment in patients with Huntington's disease. Neurology, 41:156-8.
51. Satou T, Anderson AJ, ltoh T, et al. 2001. Repetitive administration of tetrabenazine induces irreversible changes in locomotion and morphology of the substantia nigra in rats. Exp Toxicol Pathol, 53:303-8.
52. Sattes H. 1960. The treatment of chorea minor with the monoamine liberator "Nitoman." Psychiatr Neural Neurochirurg (Basel), 140:13.
53. Sattes H, Hase E, 1964. Die Behandherd Extrapyramidaler Hypokinesien unto besonderer Befficksichtigung der choTea Huntington. Psychiatr Neurol Neurochirurg (Aust), 67:289.
54. Scahill L, Chappell PB, King RA, et al. 2000. Pharmacologic treatment of tic disorders. Child Adolesc Psychiatr Clin N Am, 9:99-117.
55. Scherman D, Henry JP. 1982. Acido-basic properties of the catecholamine uptake inhibitors tetrabenazine and dihydrotetrabenazine. Biochimie, 64:915-21.
56. Schott K, Ried S, Stevens I, et al. 1989. Neuroleptically induced dystonia in Huntington's disease: a case report. Eur Neurol, 29:39-40.
57. Scott BL. 2000. Evaluation and treatment of dystonia. South Med J, 93:746-51.
58. Shoulson I, Goldblatt D. 1981. Huntington's disease (HD): effect of tetrabenazine and antipsychotic drugs on motoric features. Neurology, 31:79.
59. Simpson GM. 2000. The treatment of tardive dyskinesia and tardive dystonia. J Clin Psychiatry, 61 (Suppl 4):39-44.
60. Smith M. 1960. Clinical Comparison of Tetrabenazine (Ro 1-9569), reserpine and placebo in chronic schizophrenia. Dis Nerv Syst, 21:120-3.
61. Smith JM, Baldessarini RJ. 1980. Changes in prevalence, severity and recovery in tardive dyskinesia with age Arch Gen Psychiatry, 37:1368-73.
62. Storey E, Lloyd J. 1997. Tardive tremor. Mov Disord, 12:808-10.
63. Stumpf W. 1960. Untersuchungen uber 'Nitoman'. Psychiatr Neural, 140:63-8.
64. Swash M, Roberts AH, Zakko H, et al. 1972. Treatment of involuntary movement disorders with tetrabenazine. J Neurol Neurosurg Psychiatry, 35:186-91.
65. Tarsy D. 2000. Tardive Dyskinesia. Curr Treat Options Neurol, 2:205-14.
66. The Huntington's Disease Collaborative Research Group. 1993. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell, 72:971-83.
67. Toglia JU, McGlamery M, Sambandham RR. 1978. Tetrabenazine in the treatment of Huntington's chorea and other hyperkinetic movement disorders. J Clin Psychiatry, 39:81-7.
68. Van Vugt JP, Siesling S, Vergeer M, et al. 1997. Clozapine versus placebo in Huntington's disease: a double blind randomized comparative study. J Neurol Neurosurg Psychiatry, 63:35-9.